Page last updated: 2024-10-27

fluorouracil and Dermatoses

fluorouracil has been researched along with Dermatoses in 104 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"The addition of sorafenib to gemcitabine/capecitabine provided a clinically small but statistically significant PFS benefit in HER2-negative advanced breast cancer patients whose disease progressed during/after bevacizumab."9.17Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013)
"The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)."9.15Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011)
"We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel."9.13Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. ( Bosnjak, SM; Radulovic, S; Susnjar, S, 2008)
"We retrospectively reviewed the records of 141 consecutive patients with metastatic breast cancer identified from pharmacy records as receiving capecitabine outside of a clinical trial between May 1998 and February 1999."8.82Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. ( Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V, 2005)
"Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer."7.74[Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008)
"We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy."7.74[A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy]. ( Aoyagi, H; Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kobayashi, H; Matsuyama, T; Sugihara, K; Uetake, H; Yasuno, M, 2008)
"The combined use of ablative Er:YAG laser and topical 5-fluorouracil chemotherapy may be considered as an effective treatment option in cases of giant keratoacanthoma when conventional surgery is not indicated."7.72Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. ( Elsner, P; Fuchs, S; Thiele, JJ; Ziemer, M, 2004)
" The most commonly observed adverse events by KRAS tumor status included dermatitis acneiform and pruritus."6.76The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. ( Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011)
"Keratoacanthoma is a common, benign cutaneous neoplasm that displays rapid growth on sun-exposed skin."5.31Topical 5-fluorouracil as primary therapy for keratoacanthoma. ( Gray, RJ; Meland, NB, 2000)
"A keratoacanthoma is a benign epithelial growth most often found in sun-exposed skin of the elderly."5.26Treatment of multiple keratoacanthomas with intralesional fluorouracil. ( Eubanks, SW; Gentry, RH; May, DL; Patterson, JW, 1982)
"The addition of sorafenib to gemcitabine/capecitabine provided a clinically small but statistically significant PFS benefit in HER2-negative advanced breast cancer patients whose disease progressed during/after bevacizumab."5.17Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013)
"The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)."5.15Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011)
"We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel."5.13Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. ( Bosnjak, SM; Radulovic, S; Susnjar, S, 2008)
"We retrospectively reviewed the records of 141 consecutive patients with metastatic breast cancer identified from pharmacy records as receiving capecitabine outside of a clinical trial between May 1998 and February 1999."4.82Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. ( Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V, 2005)
"Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer."3.74[Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008)
"We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy."3.74[A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy]. ( Aoyagi, H; Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kobayashi, H; Matsuyama, T; Sugihara, K; Uetake, H; Yasuno, M, 2008)
"The combined use of ablative Er:YAG laser and topical 5-fluorouracil chemotherapy may be considered as an effective treatment option in cases of giant keratoacanthoma when conventional surgery is not indicated."3.72Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. ( Elsner, P; Fuchs, S; Thiele, JJ; Ziemer, M, 2004)
"The effects of cisplatin and 5-fluorouracil on wound breaking strength and the rate of closure of an orocutaneous fistula were studied in 80 male rodents."3.68The effects of chemotherapy on murine wound healing and orocutaneous fistula closure. ( al-Sarraf, M; Grabow, D; Guan, ZX; Ledgerwood, AM; Lucas, CE; Weaver, A; Whittle, T, 1990)
" Vitamin A acid and benzoyl peroxide have brought significant advances in the topical treatment of acne."3.66[Advances in topical therapy of skin diseases (author's transl)]. ( Happle, R, 1979)
" The most commonly observed adverse events by KRAS tumor status included dermatitis acneiform and pruritus."2.76The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. ( Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011)
"Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter."2.73A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. ( Adimi, P; Andersen, LJ; Bastholt, L; Larsen, S; Lindeløv, B; McCulloch, T; Serup-Hansen, E, 2007)
" In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))."2.73Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007)
" In 10 of 19 patients who had not responded (SD, PD), three additional courses of chemotherapy were combined with sCMT (with 25 sCMT applications)."2.71Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study. ( Ahlers, O; Deja, M; Dräger, J; Felix, R; Hildebrandt, B; Kerner, T; Löffel, J; Riess, H; Stroszczynski, C; Wust, P, 2004)
" We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma."2.70Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002)
"5-fluorouracil (5-FU) has proven to be an effective therapy in the treatment of a variety of dermatologic conditions."2.58Topical 5-fluorouracil in dermatologic disease. ( Alkousakis, T; Cameron, MC; Fathi, R; Prince, GT, 2018)
"5-fluorouracil has proven to be an effective therapy in the treatment of a variety of dermatologic conditions."2.58Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review. ( Alkousakis, T; Cameron, MC; Fathi, R; Prince, GT, 2018)
"Salicylic acid (SA) was superior to placebo with a risk ratio (RR) for cure of 1·60 [95% confidence interval (CI) 1·15-2·24]."2.47Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials. ( Gibbs, S; Holland, R; Kwok, CS, 2011)
"Combinations for metastatic breast cancer that appear in recently approved labeling include ixabepilone with capecitabine, and the targeted biological agent lapatinib in combination with capecitabine."2.45Current combination chemotherapy regimens for metastatic breast cancer. ( Schwartz, J, 2009)
"Lapatinib was administered at doses ranging from 1000 to 1500 mg/day as monotherapy (n=928) or in combination with paclitaxel or capecitabine (n=491)."2.45Analysis of dermatologic events in patients with cancer treated with lapatinib. ( Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW, 2009)
"5 fluorouracil therapy was terminated and the patients were shifted to interferon therapy subsequently."1.51Severe necrotising inflammatory skin reaction to topical 5-fluorouracil. ( Gokhale, NS, 2019)
" The frequency of grade 3 and 4 adverse effects were comparatively assessed in each treatment arm."1.39Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. ( Bano, N; Mateen, A; Najam, R, 2013)
"Capecitabine was designed to generate 5FU via the thymidine phosphorylase (TP) enzyme, preferentially expressed in tumoral tissues."1.35Candidate mechanisms for capecitabine-related hand-foot syndrome. ( Etienne-Grimaldi, MC; Formento, JL; Francoual, M; Hofman, P; Lacour, JP; Lassalle, S; Mari, M; Milano, G, 2008)
"The clinical diagnosis of multiple pyogenic granulomas was confirmed by histological examination."1.33Multiple periungual pyogenic granulomas following systemic 5-fluorouracil. ( Cooray, P; Curr, N; Gin, D; Murugasu, A; Saunders, H; Schwarz, M, 2006)
"Keratoacanthoma is a common, benign cutaneous neoplasm that displays rapid growth on sun-exposed skin."1.31Topical 5-fluorouracil as primary therapy for keratoacanthoma. ( Gray, RJ; Meland, NB, 2000)
"5-Fluorouracil (5-FU) is an antimetabolite frequently used in the treatment of cancer."1.29Dermatological toxicity from chemotherapy containing 5-fluorouracil. ( Campanella, GA; Carrieri, G; Colucci, G; Leo, S; Tatulli, C; Taveri, R, 1994)
"Diarrhea was the dose-limiting toxic effect and occurred more often in patients with abnormal pretreatment liver function."1.27Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983)
"A keratoacanthoma is a benign epithelial growth most often found in sun-exposed skin of the elderly."1.26Treatment of multiple keratoacanthomas with intralesional fluorouracil. ( Eubanks, SW; Gentry, RH; May, DL; Patterson, JW, 1982)
"The 12th case of Bowen's disease, presented here, offers an alternative method of treatment using 5-fluorouracil combined with a keratolytic ointment."1.26Bowen's disease of the nail bed: a case presentation and review of the literature. ( Defiebre, BK, 1978)

Research

Studies (104)

TimeframeStudies, this research(%)All Research%
pre-199050 (48.08)18.7374
1990's7 (6.73)18.2507
2000's25 (24.04)29.6817
2010's17 (16.35)24.3611
2020's5 (4.81)2.80

Authors

AuthorsStudies
Rivard, SC1
Soueidy, C1
Skaff, S1
Stephan, F1
Kattan, J1
Gokhale, NS1
Gupta, S2
Jangra, RS1
Gupta, SS1
Gujrathi, AV1
Chiang, TY1
Hsu, HC1
Jane, SW1
Chen, SC1
Searle, T1
Al-Niaimi, F1
Ali, FR1
Dalenc, F1
Ribet, V1
Rossi, AB1
Guyonnaud, J1
Bernard-Marty, C1
de Lafontan, B1
Salas, S1
Ranc Royo, AL1
Sarda, C1
Levasseur, N1
Massabeau, C1
Levecq, JM1
Dulguerova, P1
Guerrero, D1
Sibaud, V1
Wenande, E1
Erlendsson, AM1
Haedersdal, M1
Prince, GT2
Cameron, MC2
Fathi, R2
Alkousakis, T2
Takada, S1
Sagawa, T1
Fujikawa, K1
Tahatsu, K1
Fukai, Y1
Hashishita, H1
Takahashi, Y1
Endo, M1
Schwartzberg, LS1
Tauer, KW1
Hermann, RC1
Makari-Judson, G1
Isaacs, C1
Beck, JT1
Kaklamani, V1
Stepanski, EJ1
Rugo, HS1
Wang, W1
Bell-McGuinn, K1
Kirshner, JJ1
Eisenberg, P1
Emanuelson, R1
Keaton, M1
Levine, E1
Medgyesy, DC1
Qamar, R1
Starr, A1
Ro, SK1
Lokker, NA1
Hudis, CA1
Bano, N1
Najam, R1
Mateen, A1
Comfere, NI1
Ikediobi, ON1
Peters, MS1
el-Azhary, RA1
Gibson, LE1
Peeters, M1
Price, TJ1
Cervantes, A1
Sobrero, AF1
Ducreux, M1
Hotko, Y1
André, T1
Chan, E1
Lordick, F1
Punt, CJ1
Strickland, AH1
Wilson, G1
Ciuleanu, TE1
Roman, L1
Van Cutsem, E1
Tian, Y1
Sidhu, R1
Yeung, R1
McConnell, Y1
Warkentin, H1
Graham, D1
Warkentin, B1
Joseph, K1
Doll, CM1
Ardavanis, A1
Orphanos, G1
Skafida, S1
Basioukas, S1
Rigatos, G1
Lacouture, ME2
Laabs, SM1
Koehler, M1
Sweetman, RW1
Preston, AJ1
Di Leo, A1
Gomez, HL1
Salazar, VM1
Byrne, JA1
Koch, KM1
Blackwell, KL1
Fujii, C1
Anami, S1
Fujino, M1
Yasui, Y1
Fujita, M1
Inoue, M1
Nakayama, T1
Kamigaki, S1
Tatsuta, M1
Furukawa, H1
Susnjar, S1
Bosnjak, SM1
Radulovic, S1
Matsuyama, T1
Uetake, H1
Aoyagi, H1
Kobayashi, H1
Ishikawa, T2
Iida, S1
Higuchi, T1
Yasuno, M1
Enomoto, M1
Sugihara, K1
Lee, YJ1
Lee, HJ1
Jeong, KC1
Kang, JG1
Lee, SH1
Kim, YT1
Vano-Galvan, S1
Moreno, C1
Medina, J1
Pérez-García, B1
García-López, JL1
Jaén, P1
Schwartz, J1
Moore, AY1
Ceilley, RI1
Kwok, CS1
Holland, R1
Gibbs, S1
Grossberg, AL1
Gaspari, AA1
Stintzing, S1
Fischer von Weikersthal, L1
Vehling-Kaiser, U1
Stauch, M1
Hass, HG1
Dietzfelbinger, H1
Oruzio, D1
Klein, S1
Zellmann, K1
Decker, T1
Schulze, M1
Abenhardt, W1
Puchtler, G1
Kappauf, H1
Mittermüller, J1
Haberl, C1
Giessen, C1
Moosmann, N1
Heinemann, V1
Mitchell, EP1
Piperdi, B1
Shearer, H1
Iannotti, N1
Pillai, MV1
Xu, F1
Yassine, M1
Thaler, J1
Karthaus, M1
Mineur, L1
Greil, R1
Letocha, H1
Hofheinz, R1
Fernebro, E1
Gamelin, E1
Baños, A1
Köhne, CH1
Okabe, S1
Tanami, H1
Kuwabara, H1
Fukahara, T1
Udagawa, M1
Ootsukasa, S1
Arai, T1
Maruyama, S1
Murase, N1
Yamashita, H1
Iwai, T1
Blugerman, G1
Schavelzon, D1
Dreszman, R1
Hildebrandt, B1
Dräger, J1
Kerner, T1
Deja, M1
Löffel, J1
Stroszczynski, C1
Ahlers, O1
Felix, R1
Riess, H1
Wust, P1
Thiele, JJ1
Ziemer, M1
Fuchs, S1
Elsner, P1
Larkö, O1
Hennessy, BT1
Gauthier, AM1
Michaud, LB1
Hortobagyi, G1
Valero, V1
Davis, MD1
Weick, JA1
Link, JS1
Yuge, S1
Godoy, DA1
Melo, MC1
Sousa, DS1
Soares, CT1
Curr, N1
Saunders, H1
Murugasu, A1
Cooray, P1
Schwarz, M1
Gin, D1
Poligone, B1
Christensen, SR1
Lazova, R1
Heald, PW1
Larsen, S1
Serup-Hansen, E1
Andersen, LJ1
Lindeløv, B1
McCulloch, T1
Adimi, P1
Bastholt, L1
Ernst, T1
Merx, K1
Gnad-Vogt, U1
Lukan, N1
Kripp, M1
Schultheis, B1
Hochhaus, A1
Hofheinz, RD1
Milano, G1
Etienne-Grimaldi, MC1
Mari, M1
Lassalle, S1
Formento, JL1
Francoual, M1
Lacour, JP1
Hofman, P1
Jansen, GT1
Dillaha, CJ1
Honeycutt, WM1
Brenner, S1
Shohet, J1
Krakowski, A1
Ilie, B1
Carter, DM1
Balin, AK1
Bedikian, AY1
Bodey, GP1
Valdivieso, M1
Burgess, MA1
Ray, GR1
Fish, VJ1
Marmor, JB1
Rogoway, W1
Kushlan, P1
Arnold, C1
Lee, RH1
Marzoni, F1
Tsuji, T1
Nakagawa, K1
Hamada, T1
Bedwinek, JM1
Ratkin, GA1
Philpott, GW1
Wallack, M1
Perez, CA1
Heine, KG1
Goette, DK1
Eubanks, SW1
Gentry, RH1
Patterson, JW1
May, DL1
Benoldi, D1
Pezzarossa, E1
Alinovi, A1
Labrini, G1
Marcheselli, W1
de Panfilis, G1
Manfredi, G1
Noble, S1
Wagstaff, AJ1
Leo, S1
Tatulli, C1
Taveri, R1
Campanella, GA1
Carrieri, G1
Colucci, G1
Nelson, BR1
Kolansky, G1
Gillard, M1
Ratner, D1
Johnson, TM1
Landry, JC1
Koretz, MJ1
Wood, WC1
Bahri, S1
Smith, RG1
Costa, M1
Daneker, GW1
York, MR1
Sarma, PR1
Lynn, M1
McAtee, N1
Brooks, C1
Dela Rosa, T1
Singal, A1
Mohanty, S1
Bhattacharya, SN1
Baruah, MC1
Singh, N1
Gray, RJ1
Meland, NB1
Kim, JJ1
Chang, MW1
Shwayder, T1
Roth, AD1
Berney, CR1
Rohner, S1
Allal, AS1
Morel, P1
Marti, MC1
Aapro, MS1
Alberto, P1
Rees, RB2
Happle, R1
Dovzhanskiĭ, SI1
Suvorov, AP1
Breitbart, EW1
Hahn, P1
Hallberg, O1
Vikterlöf, KJ1
Wohlrab, W1
Lewis, MB1
Defiebre, BK1
Cohen, M1
Perry, HO1
Clemons, DE1
Aeling, JL1
Nuss, DD1
Ottolenghi, F1
Andreassi, L1
Sbano, E1
Fimiani, M1
Whittle, T1
Lucas, CE1
Ledgerwood, AM1
Weaver, A1
al-Sarraf, M1
Guan, ZX1
Grabow, D1
Nunnink, JC1
Krusinski, PA1
Yates, JW1
Larson, PO1
Tennstedt, D1
Lachapelle, JM1
Cobb, MW1
Pellegrini, AE1
Villani, C1
Pace, S1
Tomao, S1
Pietrangeli, D1
Pucci, G1
Bennett, R1
Epstein, E2
Goette, D1
Lowe, N1
Maibach, H1
Menn, H1
Tromovitch, T1
Bissada, NK1
Redman, JF1
Sulieman, JS1
Nevin, JE1
Melnick, I1
Baggerly, JT1
Estevez, J1
Landes, R1
Easley, CA1
Goldmann, L1
Igelman, JM1
Kitzmiller, K1
Lynch, PJ1
Stoughton, RB1
Richardson, JR1
Linton, PC1
Leadbetter, GW1
Weinstein, GD1
Zackheim, HS1
Farber, EM1
Bart, BJ1
Bean, SF1
Miller, E1
Yamamoto, K1
Sasaki, S1
Schuppli, R2
Spencer, SK1
Kierland, RR1
Midana, A1
Leigheb, G1
Erlanger, M1
Martz, G1
Ott, F1
Storck, H1
Rieder, J1
Kessler, S1
Nazzaro, P1
Alden, HS1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Topical 5-fluorouracil Versus Topical Latanoprost With Microneedling in Localized Stable Vitiligo: A Randomised Clinical Trial[NCT05513924]Phase 2/Phase 340 participants (Actual)Interventional2022-03-15Completed
A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy[NCT00493636]Phase 2160 participants (Actual)Interventional2007-06-30Completed
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer[NCT00339183]Phase 31,186 participants (Actual)Interventional2006-06-30Completed
Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities[NCT03370406]Phase 130 participants (Anticipated)Interventional2018-08-03Recruiting
Comparison of 70% Pyruvic Acid Solution and Duofilm Solution in Treatment of Plantar Wart[NCT02151630]Phase 2/Phase 360 participants (Anticipated)Interventional2014-05-31Recruiting
Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts[NCT05520658]60 participants (Anticipated)Interventional2022-07-01Recruiting
A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab[NCT00332163]Phase 295 participants (Actual)Interventional2006-04-30Completed
A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer[NCT00508404]Phase 2154 participants (Actual)Interventional2007-05-09Completed
A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726]90 participants (Anticipated)Interventional2023-05-16Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Duration of Overall Response

Duration of overall response was calculated as the time (days) from first documentation of CR or PR (whichever status is recorded first) until the first date that recurrent or progressive disease (PD) or death is objectively documented. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: Period measured from the first documentation of complete or partial response (whichever status is recorded first) until the first date that recurrent or progressive disease or death is objectively documented.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)94
B (Placebo + Gemcitabine or Capecitabine)147

Overall Response Rate

Overall response rate was defined as the proportion of participants experiencing complete response (CR) and partial response (PR) as best overall response. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: The overall tumor burden at baseline will be compared with subsequent measurements up to the date of first documented disease progression or the date of death due to any cause, if before progression, assessed up to 39 months.

Interventionpercentage of participants (Number)
A (Sorafenib + Gemcitabine or Capecitabine)19.8
B (Placebo + Gemcitabine or Capecitabine)12.7

Overall Survival

(NCT00493636)
Timeframe: From the date of randomization to date of death due to any cause, assessed up to 56 months.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)407
B (Placebo + Gemcitabine or Capecitabine)348

Progression Free Survival

(NCT00493636)
Timeframe: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)103
B (Placebo + Gemcitabine or Capecitabine)81

Time to Progression

(NCT00493636)
Timeframe: Calculated as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical, whichever is earlier), assessed up to 39 months.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)111
B (Placebo + Gemcitabine or Capecitabine)82

Duration of Response

"Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months

Interventionmonths (Median)
Wild-type KRAS - Panitumumab Plus FOLFIRI7.6
Wild-type KRAS - FOLFIRI Alone6.6
Mutant KRAS - Panitumumab Plus FOLFIRI6.0
Mutant KRAS - FOLFIRI Alone7.4

Overall Survival

Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date. (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months

Interventionmonths (Median)
Wild-type KRAS - Panitumumab Plus FOLFIRI14.5
Wild-type KRAS - FOLFIRI Alone12.5
Mutant KRAS - Panitumumab Plus FOLFIRI11.8
Mutant KRAS - FOLFIRI Alone11.1

Percentage of Participants With an Objective Response

Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00339183)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.

Interventionpercentage of participants (Number)
Wild-type KRAS - Panitumumab Plus FOLFIRI35.35
Wild-type KRAS - FOLFIRI Alone9.82
Mutant KRAS - Panitumumab Plus FOLFIRI13.36
Mutant KRAS - FOLFIRI Alone13.92

Progression-free Survival (PFS)

"Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.

Interventionmonths (Median)
Wild-type KRAS - Panitumumab Plus FOLFIRI5.9
Wild-type KRAS - FOLFIRI Alone3.9
Mutant KRAS - Panitumumab Plus FOLFIRI5.0
Mutant KRAS - FOLFIRI Alone4.9

Time to Disease Progression

"Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months

Interventionmonths (Median)
Wild-type KRAS - Panitumumab Plus FOLFIRI7.3
Wild-type KRAS - FOLFIRI Alone5.3
Mutant KRAS - Panitumumab Plus FOLFIRI5.5
Mutant KRAS - FOLFIRI Alone5.5

Number of Participants With Adverse Events (AEs)

"A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.

,
Interventionparticipants (Number)
Any adverse eventSerious adverse eventLeading to discontinuation of any study drugTreatment-related adverse event (TRAE)Serious treatment-related adverse eventTRAE leading to discontinuation of any study drug
FOLFIRI Alone573175645429034
Panitumumab Plus FOLFIRI58423212357712497

Best Overall Response Rate

Best overall response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) while on study. Tumor response was assessed by CT scan or MRI of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified RECIST criteria. CR: Disappearance of all target and non-target lesions and no new lesions. PR: Either the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or PD (≥ 25% increase in lesion size) and no new lesions, or, at least a 30% decrease in the size of target lesions with no progression of existing non-target lesions, and no new lesions. (NCT00332163)
Timeframe: Response was assessed at Weeks 9 and 13 and then every 8 weeks for the Q2W regimen, or at Weeks 10, 14, 22 and then every 9 weeks for the Q3W regimen until the end of treatment; median treatment duration was 13 and 17 weeks in each group respectively.

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment15
Reactive Skin Treatment11

Overall Survival

Overall Survival is defined as the time from the date of randomization to the date of death. Participants who did not die while on study or who were lost-to-follow-up were censored at their last contact date. Overall survival was analyzed using all data regardless of whether it was collected during second- or third-line treatment. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.

Interventionmonths (Median)
Pre-emptive Skin Treatment11.2
Reactive Skin Treatment13.6

Percentage of Participants With Any Grade 2 or Higher Skin Toxicity of Any Type During the 6-week Skin Treatment Period

"The percentage of participants who developed at least 1 incidence of ≥ grade 2 skin toxicities of any type during the 6-week skin treatment period. Analysis of this endpoint was based on adverse event data associated with the Skin and Subcutaneous Tissue Disorders system organ class. Adverse events were graded according to the National Cancer Institute (NCI) CTCAE version 3.0." (NCT00332163)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment40
Reactive Skin Treatment62

Percentage of Participants With Panitumumab Dose Reductions Due to the Specific Skin Toxicities of Interest

(NCT00332163)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment6
Reactive Skin Treatment11

Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period

Skin toxicities were assessed by the study clinician and graded according to the modified Common Toxicity Criteria for Adverse Events (CTCAE) v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment29
Reactive Skin Treatment62

Progression-free Survival

Defined as the time from the date of randomization to the first date of observed disease progression or death due to any cause (whichever comes first). Participants who were alive and had not progressed while on study were censored at the date of last progression-free tumor assessment. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.

Interventionmonths (Median)
Pre-emptive Skin Treatment4.7
Reactive Skin Treatment4.1

Rate of Disease Control at First Scheduled Assessment

Tumor response was assessed by CT scan or MRI of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified response evaluation criteria in solid tumors (RECIST). Disease control rate is defined as the percentage of participants with a CR, PR or stable disease (SD) at the Week 9/10 assessment visit and a corresponding response (CR or PR) confirmed at the Week 13/14 assessment visit for the Q2W/Q3W regimens. SD: Neither sufficient shrinkage or increase in target lesions to qualify for PR or PD, with no progression of non-target lesions and no new lesions. (NCT00332163)
Timeframe: Week 9 with confirmed response at Week 13 for the FOLFIRI and panitumumab Q2W regimen or at Week 10 with confirmed response at Week 14 for the irinotecan and panitumumab Q3W regimen.

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment63
Reactive Skin Treatment64

Response Rate at First Scheduled Assessment

Tumor response was assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified response evaluation criteria in solid tumors (RECIST). Response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) at the Week 9/10 assessment visit and a corresponding CR or PR confirmed at the Week 13/14 assessment visit for the Q2W/Q3W regimens. CR: Disappearance of all target and non-target lesions and no new lesions. PR: Either the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease (PD; ≥ 25% increase in lesion size) and no new lesions, or, at least a 30% decrease in the size of target lesions with no progression of existing non-target lesions, and no new lesions. (NCT00332163)
Timeframe: Week 9 with confirmed response at Week 13 for the FOLFIRI and panitumumab Q2W regimen or at Week 10 with confirmed response at Week 14 for the irinotecan and panitumumab Q3W regimen.

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment6
Reactive Skin Treatment6

Time to First Most Severe Specific Grade 2 or Higher Skin Toxicities of Interest

Time to the first most severe grade ≥ 2 of all the specific skin-related toxicities of interest was defined as the time from the first dose of panitumumab to the date of the first occurrence of the most severe specific ≥ grade 2 skin toxicity of interest during the 6-week skin treatment period. Participants who did not experience any specific skin-related toxicity of grade ≥ 2 were censored at their last skin toxicity assessment during the 6-week skin toxicity assessment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks

Interventionweeks (Median)
Pre-emptive Skin TreatmentNA
Reactive Skin Treatment2.7

Time to First Occurrence of Specific Grade 2 or Higher Skin Toxicities of Interest

The time to the first occurrence of specific grade 2 or higher skin toxicities of interest was defined as the time from the first dose of panitumumab to the date of first occurrence of specific ≥ grade 2 skin toxicities of interest. Participants who did not experience specific skin-related toxicities were censored at their last skin toxicity assessment during the skin toxicity assessment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks

Interventionweeks (Median)
Pre-emptive Skin TreatmentNA
Reactive Skin Treatment2.1

Time to Progression

"Time from the date of randomization to the date of observed disease progression or death due to disease progression. Participants who did not have documented disease progression were censored at the date of last tumor assessment; participants who died for reasons other than disease progression while on study were censored at the date of death. PD: At least a 20% increase in the size of target lesions, recorded since the treatment started, or at least a 25% increase in size of non-target lesions and the lesion(s) measure > 10 mm in one dimension, or the appearance of one or more new lesions.~Time to progression was analyzed using the Kaplan-Meier method. This analysis excludes any data collected during follow-up for participants who began third-line treatment." (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.

Interventionmonths (Median)
Pre-emptive Skin Treatment4.9
Reactive Skin Treatment4.1

Time to Treatment Failure

Time-to-treatment failure is defined as the time from the date of randomization to the first date of any of the following events: discontinuation of study therapy due to any reason (except for complete response and curative surgery), progression of disease, or death due to any cause. Participants who did not discontinue, who were still alive, and who did not have disease progression were censored at the date of last contact. Time to treatment failure was analyzed using the Kaplan-Meier method. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.

Interventionmonths (Median)
Pre-emptive Skin Treatment3.1
Reactive Skin Treatment4.2

Change From Baseline in Overall Dermatologic Quality of Life Index (DLQI) Score

Skin-related quality of life was assessed using the DLQI. The DLQI questionnaire asks participants to evaluate the degree that their skin condition has affected their quality of life in the last week. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); The DLQI score is calculated by summing the scores for all questions, resulting in a maximum of 30 and a minimum of 0; higher scores indicate a more impaired quality of life. (NCT00332163)
Timeframe: Baseline and Weeks 2, 3, 4, 5, 6 and 7

,
Interventionunits on a scale (Mean)
Baseline (n=46, 44)Change from Baseline to Week 2 (n=42, 41)Change from Baseline to Week 3 (n=44, 42)Change from Baseline to Week 4 (n=42, 42)Change from Baseline to Week 5 (n=44, 42)Change from Baseline to Week 6 (n=42, 38)Change from Baseline to Week 7 (n=40, 40)
Pre-emptive Skin Treatment0.30.71.31.71.31.62.0
Reactive Skin Treatment0.11.64.23.82.72.32.6

Most Severe Specific Grade 2 or Higher Skin Toxicities of Interest

The percentage of participants with a most severe grade of 2, 3 or 4 specific skin toxicity of interest reported during the 6-week skin treatment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks

,
Interventionpercentage of participants (Number)
Grade 2Grade 3Grade 4
Pre-emptive Skin Treatment2360
Reactive Skin Treatment40210

Disease Control Rate

"The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST v1.0 criteria as assessed by the Investigator.~Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks

Interventionpercentage of participants (Number)
Wild-type KRAS90.59
Mutant KRAS89.66

Duration of Response

Duration of response was calculated only for those participants who had a confirmed complete or partial response, and is defined as the time from first confirmed response to first observed progression. For participants who responded and did not progress by the analysis data cut-off date, duration of response was censored at their last evaluable disease assessment date. Duration of response was analyzed using the Kaplan-Meier method. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS13.0
Mutant KRAS7.4

Duration of Stable Disease

Duration of stable disease was calculated only for participants with a best response of stable disease and is defined as the time from enrollment to first observed PD. For participants who did not progress by the analysis data cut-off date, duration of SD was censored at their last evaluable disease assessment date. Duration of stable disease was estimated using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS5.9
Mutant KRAS6.1

Objective Response by 17 Weeks

The percentage of participants with a best response of complete response or partial response by Week 17. Disease assessments are based on investigator review of scans using modified RECIST V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders. (NCT00508404)
Timeframe: Up to Week 17

Interventionpercentage of participants (Number)
Wild-type KRAS49.41
Mutant KRAS34.48

Objective Response Rate

"Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments are based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders.~Complete Response (CR): disappearance of all target and non-target lesions and no new lesions.~Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks

Interventionpercentage of participants (Number)
Wild-type KRAS56.47
Mutant KRAS37.93

Progression-free Survival

Progression-free survival is the time from the date of enrollment to the date of first observed progression or death, whichever comes first. Participants who were alive and did not progress by the analysis data cut-off date were censored at the last evaluable disease assessment date. Progression-free survival was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS8.9
Mutant KRAS7.2

Resection Rate

The percentage of participants who underwent a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

Interventionpercentage of participants (Number)
Wild-type KRAS15.12
Mutant KRAS6.78

Time to Disease Progression

Time to progression is the time from the enrollment date to the date of first observed progression. For participants who had not progressed by the analysis data cutoff date, time to progressive disease was censored at their last evaluable disease assessment date. Time to disease progression was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS11.2
Mutant KRAS7.3

Time to Disease Relapse Following Surgical Intervention

Calculated only for those participants who underwent surgical intervention, and defined as the time from the date of first post-intervention radiographic disease assessment to the date of first observed PD. Participants with no post-intervention disease assessment had their time to relapse set to zero and censored in the analysis. Participants that had evidence of progression / recurrence at their first post-intervention disease assessment had a time to relapse of zero. For participants who had not progressed by the analysis data cut-off date, time to relapse was censored at the date of their last evaluable disease assessment. Time to relapse was analyzed using Kaplan-Meier metjhods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRASNA
Mutant KRASNA

Time to Initial Objective Response

Time to response is the time from the date of enrollment to the date of first confirmed complete or partial response. Participants with a best response of stable disease at the analysis data cut-off date were censored at their last assessment of SD and participants with all other categories of best response were censored at the maximum observed time to a first confirmed response among all responders. Time to initial objective response was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS3.8
Mutant KRASNA

Time to Treatment Failure

Time to treatment failure is defined as the time from enrollment to the date the decision was made to end the treatment phase for any reason. For participants who remained in the treatment phase at the analysis data cut-off date, time to treatment failure was censored at the date of their last on-study assessment. Time to treatment failure was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS6.9
Mutant KRAS5.8

Reviews

21 reviews available for fluorouracil and Dermatoses

ArticleYear
5-Fluorouracil in Dermatology: The Diverse Uses Beyond Malignant and Premalignant Skin Disease.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2021, 03-01, Volume: 47, Issue:3

    Topics: Adrenal Cortex Hormones; Cicatrix; Combined Modality Therapy; Cosmetic Techniques; Dermatitis; Derma

2021
Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders.
    Seminars in cutaneous medicine and surgery, 2017, Volume: 36, Issue:4

    Topics: Administration, Cutaneous; Anesthetics, Local; Antineoplastic Agents; Cicatrix; Cosmetic Techniques;

2017
Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review.
    Journal of drugs in dermatology : JDD, 2018, Mar-01, Volume: 17, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Cicatrix, Hypertrophic; Fluorouracil; Humans; Injections,

2018
Topical 5-fluorouracil in dermatologic disease.
    International journal of dermatology, 2018, Volume: 57, Issue:10

    Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Skin Diseases

2018
Pharmacogenetics in dermatology: a patient-centered update.
    International journal of dermatology, 2013, Volume: 52, Issue:8

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo

2013
Analysis of dermatologic events in patients with cancer treated with lapatinib.
    Breast cancer research and treatment, 2009, Volume: 114, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic

2009
Current combination chemotherapy regimens for metastatic breast cancer.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Dec-01, Volume: 66, Issue:23 Suppl 6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2009
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders.
    The Journal of dermatological treatment, 2009, Volume: 20, Issue:6

    Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic

2009
Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders.
    The Journal of dermatological treatment, 2012, Volume: 23, Issue:2

    Topics: Antimetabolites, Antineoplastic; Fluorouracil; Skin Diseases

2012
Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials.
    The British journal of dermatology, 2011, Volume: 165, Issue:2

    Topics: Administration, Topical; Adult; Anti-Infective Agents; Antibiotics, Antineoplastic; Antimetabolites,

2011
Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials.
    The British journal of dermatology, 2011, Volume: 165, Issue:2

    Topics: Administration, Topical; Adult; Anti-Infective Agents; Antibiotics, Antineoplastic; Antimetabolites,

2011
Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials.
    The British journal of dermatology, 2011, Volume: 165, Issue:2

    Topics: Administration, Topical; Adult; Anti-Infective Agents; Antibiotics, Antineoplastic; Antimetabolites,

2011
Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials.
    The British journal of dermatology, 2011, Volume: 165, Issue:2

    Topics: Administration, Topical; Adult; Anti-Infective Agents; Antibiotics, Antineoplastic; Antimetabolites,

2011
Topical antineoplastic agents in the treatment of mucocutaneous diseases.
    Current problems in dermatology, 2011, Volume: 40

    Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Diterpenes; Fluorouracil; Humans; I

2011
Photodynamic therapy.
    The Australasian journal of dermatology, 2005, Volume: 46 Suppl 3

    Topics: Administration, Topical; Aminolevulinic Acid; Antimetabolites, Antineoplastic; Cryotherapy; Fluorour

2005
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase

2005
Dermatological aspects of aging.
    The Medical clinics of North America, 1983, Volume: 67, Issue:2

    Topics: Adult; Aged; Aging; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatitis; Female; Fl

1983
Topical chemotherapy with 5-fluorouracil. A review.
    Journal of the American Academy of Dermatology, 1981, Volume: 4, Issue:6

    Topics: Administration, Topical; Chemical Phenomena; Chemistry; Dermatitis, Atopic; Dermatitis, Contact; Fem

1981
Tretinoin. A review of its pharmacological properties and clinical efficacy in the topical treatment of photodamaged skin.
    Drugs & aging, 1995, Volume: 6, Issue:6

    Topics: Administration, Topical; Animals; Cell Transformation, Neoplastic; Clinical Trials as Topic; Drug Th

1995
Current dermatologic therapy.
    Cutis, 1976, Volume: 18, Issue:4

    Topics: Acne Vulgaris; Administration, Topical; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antifungal A

1976
Newer treatment in dermatology.
    Southern medical journal, 1975, Volume: 68, Issue:11

    Topics: Acne Vulgaris; Adrenal Cortex Hormones; Antifungal Agents; Antineoplastic Agents; Carotenoids; Derma

1975
The action of antimetabolites in the skin: methotrexate for psoriasis.
    Advances in biology of skin, 1972, Volume: 12

    Topics: Carcinoma, Basal Cell; Cell Division; DNA; Fluorouracil; Humans; Injections, Intradermal; Keratosis;

1972
Topical antimetabolites.
    Annual review of medicine, 1970, Volume: 21

    Topics: Antimetabolites; Antineoplastic Agents; Carcinoma, Basal Cell; Fluorouracil; Folic Acid Antagonists;

1970
The metabolism and pharmacology of 5-fluorouracil.
    Journal of surgical oncology, 1971, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Alopecia; Animals; Breast Neoplasms; Carbon Isotopes; Cell Division; Chromosome Aber

1971

Trials

13 trials available for fluorouracil and Dermatoses

ArticleYear
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.
    European journal of cancer care, 2018, Volume: 27, Issue:1

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors;

2018
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-15, Volume: 19, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2008, Volume: 16, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-

2008
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
    British journal of cancer, 2011, Jul-12, Volume: 105, Issue:2

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2011
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
    BMC cancer, 2012, Sep-29, Volume: 12

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2012
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
    Journal of medical and dental sciences, 2002, Volume: 49, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp

2002
Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2004, Volume: 20, Issue:3

    Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth

2004
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati

2007
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
    British journal of cancer, 2007, Dec-03, Volume: 97, Issue:11

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di

2007
Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential.
    British journal of cancer, 2000, Volume: 83, Issue:12

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Arteries; Bleo

2000
[Controlled clinical studies of a new wart medication based on fluorouracil].
    Zeitschrift fur Hautkrankheiten, 1979, Oct-01, Volume: 54, Issue:19

    Topics: Adolescent; Adult; Aged; Baths; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic;

1979

Other Studies

70 other studies available for fluorouracil and Dermatoses

ArticleYear
Surfer with Photodistributed Erythematous, Scaling Eruption.
    American family physician, 2021, 12-01, Volume: 104, Issue:6

    Topics: Animal Scales; Animals; Fluorouracil; Humans; Immunosuppressive Agents; Male; Middle Aged; Skin Dise

2021
Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report.
    Anti-cancer drugs, 2023, 01-01, Volume: 34, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cellulitis; Cetu

2023
Severe necrotising inflammatory skin reaction to topical 5-fluorouracil.
    Indian journal of ophthalmology, 2019, Volume: 67, Issue:12

    Topics: Administration, Ophthalmic; Antimetabolites, Antineoplastic; Conjunctival Neoplasms; Drug Eruptions;

2019
A novel method to enhance efficacy of topical drugs by condom occlusion in penile dermatoses.
    Postgraduate medical journal, 2020, Volume: 96, Issue:1135

    Topics: Administration, Topical; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Balanitis; Condo

2020
EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:10

    Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2020
Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
    Asian Pacific journal of cancer prevention : APJCP, 2018, Aug-24, Volume: 19, Issue:8

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab;

2018
Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2013
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
    Radiation oncology (London, England), 2015, Apr-17, Volume: 10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem

2015
Coincidential successful treatment of Jessner-Kanof disease with chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylati

2008
[Management of hand-foot syndrome in patient treated with capecitabine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:8

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil

2008
[A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:12

    Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Fluorouracil; Foot; Hand; Humans; Male; Middle Age

2008
An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul

2009
Perforating dermatosis in a patient receiving bevacizumab.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2009
Intralesional use of 5-FU in subcutaneous fibrosis.
    Journal of drugs in dermatology : JDD, 2003, Volume: 2, Issue:2

    Topics: Adult; Female; Fluorouracil; Humans; Injections, Intralesional; Male; Middle Aged; Skin Diseases

2003
Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2004, Volume: 30, Issue:12 Pt 2

    Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diagnosis, Di

2004
Response of predominantly recalcitrant cutaneous warts to topical chemotherapy.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2006, Volume: 20, Issue:2

    Topics: Administration, Cutaneous; Deoxyglucose; Drug Therapy, Combination; Fluorouracil; Humans; Keratolyti

2006
Keratoacanthoma centrifugum marginatum: response to topical 5-fluorouracil.
    Journal of the American Academy of Dermatology, 2006, Volume: 54, Issue:5 Suppl

    Topics: Aged, 80 and over; Dermatologic Agents; Female; Fluorouracil; Humans; Keratoacanthoma; Leg; Methotre

2006
Multiple periungual pyogenic granulomas following systemic 5-fluorouracil.
    The Australasian journal of dermatology, 2006, Volume: 47, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Diagnosis, Differential; Fluorouracil; Granul

2006
Bazex syndrome (acrokeratosis paraneoplastica).
    Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Ear, External;

2007
Candidate mechanisms for capecitabine-related hand-foot syndrome.
    British journal of clinical pharmacology, 2008, Volume: 66, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Biopsy; Capecitabine; Cell Proliferation; Deoxycytidine; Fem

2008
Bowenoid conditions of the skin: treatment with topical 5-fluorouracil.
    Southern medical journal, 1967, Volume: 60, Issue:2

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Middle Aged; Skin Disease

1967
Mucoid milia.
    Archives of dermatology, 1984, Volume: 120, Issue:3

    Topics: Aged; Epidermal Cyst; Female; Fluorouracil; Glycosaminoglycans; Humans; Skin Diseases

1984
Phase I evaluation of oral tegafur.
    Cancer treatment reports, 1983, Volume: 67, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio

1983
Impact of adjuvant chemotherapy on cosmesis and complications in stages I and II carcinoma of the breast treated by biopsy and radiation therapy.
    International journal of radiation oncology, biology, physics, 1984, Volume: 10, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Diseases; Breast Neoplasms; Ca

1984
Different effects of topically applied 5-fluorouracil on hairy and hairless mice.
    Clinical and experimental dermatology, 1984, Volume: 9, Issue:6

    Topics: Animals; Dihydroxyphenylalanine; Fluorouracil; Hyperplasia; Hypertrophy; Melanocytes; Mice; Mice, Ha

1984
Concurrent chemotherapy and radiotherapy for nonmetastatic, Stage IV breast cancer. A pilot study by the Southeastern Cancer Study Group.
    American journal of clinical oncology, 1983, Volume: 6, Issue:2

    Topics: Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, C

1983
Treatment of multiple keratoacanthomas with fluorouracil.
    The Journal of the Kentucky Medical Association, 1983, Volume: 81, Issue:2

    Topics: Arm; Fluorouracil; Hand Dermatoses; Humans; Keratoacanthoma; Male; Middle Aged; Skin Diseases

1983
Treatment of multiple keratoacanthomas with intralesional fluorouracil.
    Journal of the American Academy of Dermatology, 1982, Volume: 7, Issue:1

    Topics: Fluorouracil; Humans; Keratoacanthoma; Male; Middle Aged; Recurrence; Skin Diseases

1982
[Retinoic acid and 5-FU mixture in the topical treatment of several skin diseases (author's transl)].
    L'Ateneo parmense. Acta bio-medica : organo della Societa di medicina e scienze naturali di Parma, 1980, Volume: 51, Issue:3

    Topics: Drug Combinations; Fluorouracil; Humans; Keratosis; Ointments; Radiation Injuries; Skin Diseases; Sy

1980
Dermatological toxicity from chemotherapy containing 5-fluorouracil.
    Journal of chemotherapy (Florence, Italy), 1994, Volume: 6, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1994
Management of linear verrucous epidermal nevus with topical 5-fluorouracil and tretinoin.
    Journal of the American Academy of Dermatology, 1994, Volume: 30, Issue:2 Pt 1

    Topics: Administration, Topical; Child; Fluorouracil; Hamartoma; Humans; Male; Neck; Occlusive Dressings; Sk

1994
Preoperative irradiation and fluorouracil chemotherapy for locally advanced rectosigmoid carcinoma: phase I-II study.
    Radiology, 1993, Volume: 188, Issue:2

    Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Mal

1993
Cryotherapy reduces fluorouracil-related side effects.
    Oncology nursing forum, 1995, Volume: 22, Issue:8

    Topics: Adult; Antimetabolites, Antineoplastic; Colostomy; Cryotherapy; Female; Fluorouracil; Humans; Male;

1995
Unusual multiple keratoacanthoma in a child successfully treated with 5-fluorouracil.
    The Journal of dermatology, 1997, Volume: 24, Issue:8

    Topics: Administration, Topical; Antimetabolites, Antineoplastic; Child, Preschool; Fluorouracil; Humans; In

1997
Topical 5-fluorouracil as primary therapy for keratoacanthoma.
    Annals of plastic surgery, 2000, Volume: 44, Issue:1

    Topics: Administration, Topical; Aged; Aged, 80 and over; Antimetabolites; Fluorouracil; Humans; Keratoacant

2000
Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus.
    Journal of the American Academy of Dermatology, 2000, Volume: 43, Issue:1 Pt 1

    Topics: Antimetabolites; Child; Drug Combinations; Fluorouracil; Hamartoma; Humans; Keratolytic Agents; Male

2000
[Advances in topical therapy of skin diseases (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1979, Jan-26, Volume: 121, Issue:4

    Topics: Acne Vulgaris; Administration, Topical; Alopecia; Benzoyl Peroxide; Dinitrochlorobenzene; Fluocortol

1979
[Use of fluorafur in the therapy of various chronic dermatoses].
    Vestnik dermatologii i venerologii, 1977, Issue:11

    Topics: Adult; Aged; Chronic Disease; Fluorouracil; Humans; Male; Middle Aged; Neurodermatitis; Psoriasis; S

1977
Acute skin reactions in postoperative breast cancer patients receiving radiotherapy plus adjuvant chemotherapy.
    AJR. American journal of roentgenology, 1978, Volume: 130, Issue:1

    Topics: Breast Neoplasms; Cobalt Radioisotopes; Cyclophosphamide; Drug Therapy, Combination; Drug-Related Si

1978
[Effect of urea on the mechanism of percutaneous permeation].
    Dermatologica, 1979, Volume: 159, Issue:6

    Topics: Animals; Autoradiography; Drug Therapy, Combination; Epidermis; Fluorouracil; Guinea Pigs; Skin Abso

1979
A short survey on the use and efficacy of 5-fluorouracil in Australia.
    The Journal of dermatologic surgery and oncology, 1978, Volume: 4, Issue:3

    Topics: Aged; Australia; Carcinoma, Basal Cell; Fluorouracil; Humans; Keratosis; Skin Diseases; Skin Neoplas

1978
Bowen's disease of the nail bed: a case presentation and review of the literature.
    The Journal of hand surgery, 1978, Volume: 3, Issue:2

    Topics: Bowen's Disease; Carcinoma, Squamous Cell; Dermatologic Agents; Fluorouracil; Humans; Keratolytic Ag

1978
Local chemotherapy of skin.
    Journal of the Medical Association of Georgia, 1979, Volume: 68, Issue:1

    Topics: Fluorouracil; Humans; Skin Diseases; Skin Neoplasms

1979
Management of skin blemishes.
    Medical times, 1977, Volume: 105, Issue:6

    Topics: Aged; Electrosurgery; Fluorouracil; Humans; Keratosis; Male; Middle Aged; Skin; Skin Diseases

1977
Letter: Dermatitis medicamentosa: a pitfall for the unwary.
    Archives of dermatology, 1976, Volume: 112, Issue:8

    Topics: Adult; Female; Fluorouracil; Humans; Medication Errors; Skin Diseases

1976
[Diffuse chronic mucocutaneous candidiasis: Effects of antimycotics in vitro].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1975, Volume: 26, Issue:5

    Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis, Cutaneous; Candidiasis, Oral; Child; Chroni

1975
The effects of chemotherapy on murine wound healing and orocutaneous fistula closure.
    The American surgeon, 1990, Volume: 56, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fistula; Fluorouracil; Male; Mou

1990
Multicentric reticulohistiocytosis and cancer: a case report and review of the literature.
    Medical and pediatric oncology, 1985, Volume: 13, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arthritis; Breast Neoplasms; Carcinoma, Intraductal,

1985
Keratoacanthomas treated with Mohs' micrographic surgery (chemosurgery). A review of forty-three cases.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:5 Pt 1

    Topics: Aged; Aged, 80 and over; Female; Fluorouracil; Humans; Keratoacanthoma; Male; Microsurgery; Middle A

1987
Allergic contact dermatitis to 5-fluorouracil.
    Contact dermatitis, 1987, Volume: 16, Issue:5

    Topics: Adult; Drug Eruptions; Fluorouracil; Humans; Male; Skin Diseases; Warts

1987
Squamous cell carcinoma following fluorouracil-responsive 'keratoacanthoma'.
    Archives of dermatology, 1987, Volume: 123, Issue:8

    Topics: Aged; Carcinoma, Squamous Cell; Diagnostic Errors; Fluorouracil; Humans; Keratoacanthoma; Male; Skin

1987
Skin necrosis due to antiblastics (procedures of prevention and therapy).
    European journal of gynaecological oncology, 1986, Volume: 7, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Ext

1986
Current management using 5-fluorouracil: 1985.
    Cutis, 1985, Volume: 36, Issue:3

    Topics: Administration, Topical; Female; Fluorouracil; Humans; Male; Skin Diseases; Skin Neoplasms

1985
Condyloma acuminatum of male urethra. Successful management with 5-fluorouracil.
    Urology, 1974, Volume: 3, Issue:4

    Topics: Adult; Condylomata Acuminata; Diverticulum; Fistula; Fluorouracil; Humans; Male; Neoplasm Recurrence

1974
Arterial infusion of 5-fluorouracil as a treatment for carcinoma of the prostate.
    The Journal of urology, 1974, Volume: 112, Issue:1

    Topics: Aged; Catheterization; Fluorouracil; Humans; Iliac Artery; Injections, Intra-Arterial; Male; Middle

1974
Investigative studies with DMSO in dermatology.
    Annals of the New York Academy of Sciences, 1967, Mar-15, Volume: 141, Issue:1

    Topics: Animals; Dermatomycoses; Dimethyl Sulfoxide; Drug Eruptions; Fluocinolone Acetonide; Fluorouracil; G

1967
Tumors of the skin. Premalignment and malignant.
    Minnesota medicine, 1974, Volume: 57, Issue:10

    Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Fluorouracil; Humans; Kera

1974
Status of topical therapy.
    Clinical pharmacology and therapeutics, 1974, Volume: 16, Issue:5 Part 2

    Topics: Administration, Topical; Anti-Inflammatory Agents; Biopharmaceutics; Fluorouracil; Glucocorticoids;

1974
A new concept in the treatment of stomal stenosis.
    The Journal of urology, 1972, Volume: 108, Issue:1

    Topics: Cesium Isotopes; Child; Cicatrix; Fluorouracil; Humans; Ileum; Male; Mucus; Skin Diseases; Skin Tran

1972
Fluorouracil cream (Efudix) in dermatology.
    Drug and therapeutics bulletin, 1973, Nov-23, Volume: 11, Issue:24

    Topics: Fluorouracil; Humans; Keratosis; Psoriasis; Skin Diseases; Skin Neoplasms; Xeroderma Pigmentosum

1973
Bullous pemphigoid following the topical use of fluorouracil.
    Archives of dermatology, 1970, Volume: 102, Issue:4

    Topics: Aged; Autoantibodies; Fluorescent Antibody Technique; Fluorouracil; Humans; Keratosis; Male; Skin Di

1970
[Therapeutic effects of 5-florouracil ointment on various skin diseases].
    Gan no rinsho. Japan journal of cancer clinics, 1972, Volume: 18, Issue:3

    Topics: Adolescent; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Huma

1972
Treatment of precancerous dermatoses with topical 5-Fluorouracil.
    Asthetische Medizin, 1969, Jul-20, Volume: 18, Issue:7

    Topics: Fluorouracil; Humans; Keratosis; Ointments; Precancerous Conditions; Skin Diseases; Solutions

1969
[Practical use of immunosuppressive and cytostatic drugs in dermatological diseases].
    Minerva medica, 1970, Jul-11, Volume: 61, Issue:55

    Topics: Antineoplastic Agents; Azathioprine; Condylomata Acuminata; Fluorouracil; Humans; Immunosuppressive

1970
The aging skin: problems and their causes.
    Geriatrics, 1970, Volume: 25, Issue:4

    Topics: Aged; Aging; Arsenicals; Balanitis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorou

1970
[Treatment of dermatologic lesions using immunosuppressive agents and cytostatics].
    Munchener medizinische Wochenschrift (1950), 1970, Mar-20, Volume: 112, Issue:12

    Topics: Antineoplastic Agents; Azathioprine; Dermatomyositis; Fluorouracil; Humans; Immunosuppressive Agents

1970
5-fluorouracil (5-FU) ointment in the treatment of benign and malignant skin lesions.
    Dermatologica, 1970, Volume: 140

    Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratoacanthoma; Keratosis; L

1970
Cutaneous absorption and urinary excretion of 6-14C-5-fluorouracil ointment applicated in an ointment to healthy and diseased human skin.
    Dermatologica, 1970, Volume: 140

    Topics: Adolescent; Aged; Carbon Isotopes; Female; Fluorouracil; Humans; Male; Middle Aged; Ointments; Skin

1970
[Dermatologic aspects of cutaneous pseudocancer].
    Minerva medica, 1971, Apr-14, Volume: 62, Issue:30

    Topics: Colchicine; Diagnosis, Differential; Fluorouracil; Humans; Keratoacanthoma; Podophyllin; Skin Diseas

1971
Antimetabolites in the treatment of skin disease.
    Journal of the Medical Association of Georgia, 1968, Volume: 57, Issue:5

    Topics: Antimetabolites; Fluorouracil; Humans; Methotrexate; Skin Diseases; Skin Neoplasms

1968